Vimarsana
Biggest News Aggregation in the World

Page 3 - Obstruction Impact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Obstruction Impact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Obstruction Impact Today - Breaking & Trending Today

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day - Vimarsana News

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...

Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society - Vimarsana News

Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society

Cytokinetics, Incorporated announced that the baseline characteristics of patients randomized in SEQUOIA-HCM , the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive...

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in ... - Vimarsana News

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in ...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy - Vimarsana News

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN... | June 20, 2023

Cytokinetics Reports First Quarter 2022 Financial Results - Vimarsana News

Cytokinetics Reports First Quarter 2022 Financial Results

Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch...